Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
enGene Therapeutics Inc. (ENGN) was reported as having 3,406,023 Common Shares beneficially owned by Eventide Asset Management, LLC, equal to 5.1% of outstanding Common Shares as of September 30, 2026. Eventide is the investment adviser to Eventide Healthcare & Life Sciences Fund, which held those shares. Finny Kuruvilla, M.D., Ph.D., and Robin C. John each reported shared voting and dispositive power over the same shares. All three reporting persons disclaimed beneficial ownership.
Key Figures
Shares beneficially owned:3,406,023 sharesPercent of outstanding Common Shares:5.1%
2 metrics
Shares beneficially owned3,406,023 sharesEventide Healthcare & Life Sciences Fund held these shares as of September 30, 2026; the reporting persons disclosed overlapping interests in the same shares.
Percent of outstanding Common Shares5.1%Eventide Healthcare & Life Sciences Fund's holding as of September 30, 2026.
Key Terms
beneficially owned, sole voting power, shared dispositive power, investment adviser
4 terms
beneficially ownedregulatory
"Amount beneficially owned: 3,406,023"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerregulatory
"Sole voting power 3,406,023"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
shared dispositive powerregulatory
"Shared dispositive power 3,406,023"
investment adviserfinancial
"being the investment adviser to Eventide Healthcare & Life Sciences Fund"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ENGN stake did Eventide report?
Eventide Asset Management, LLC reported 3,406,023 enGene Common Shares, or 5.1% of outstanding Common Shares, as of September 30, 2026. Eventide reported the position as investment adviser to Eventide Healthcare & Life Sciences Fund, which held those shares; Finny Kuruvilla, M.D., Ph.D., and Robin C. John also reported shared voting and dispositive power over them.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
enGene Therapeutics Inc
(Name of Issuer)
Common Shares
(Title of Class of Securities)
29286X101
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29286X101
1
Names of Reporting Persons
Eventide Asset Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,406,023.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,406,023.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,406,023.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
29286X101
1
Names of Reporting Persons
Finny Kuruvilla, M.D. Ph. D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,406,023.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,406,023.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,406,023.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
29286X101
1
Names of Reporting Persons
Robin C. John
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,406,023.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,406,023.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,406,023.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
enGene Therapeutics Inc
(b)
Address of issuer's principal executive offices:
4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada H4R2P1
Item 2.
(a)
Name of person filing:
(i) Eventide Asset Management, LLC ("Eventide")
(ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla")
(iii) Robin C. John ("John")
(b)
Address or principal business office or, if none, residence:
Eventide, Kuruvilla and John:
One International Place, Suite 4210
Boston, Massachusetts 02110
(c)
Citizenship:
Eventide: Delaware
Kuruvilla: United States
John: United States
(d)
Title of class of securities:
Common Shares
(e)
CUSIP Number(s):
29286X101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
(i) Eventide: 3,406,023
(ii) Kuruvilla: 3,406,023
(iii) John: 3,406,023
(b)
Percent of class:
(i) Eventide: 5.1%
(ii) Kuruvilla: 5.1%
(iii) John: 5.1%
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
As of September 30, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 3,406,023 shares of the Issuer's Common Shares by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company.
As of September 30, 2026, the Eventide Healthcare & Life Sciences Fund held 3,406,023 shares of the Issuer's Common Shares, representing 5.1% of the Issuer's outstanding Common Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Eventide Asset Management, LLC
Signature:
/s/ Peter J. Luiso
Name/Title:
Peter J. Luiso, General Counsel
Date:
11/13/2026
Finny Kuruvilla, M.D. Ph. D.
Signature:
/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:
Finny Kuruvilla, M.D., Ph. D.
Date:
11/13/2026
Robin C. John
Signature:
/s/ Robin C. John
Name/Title:
Robin C. John
Date:
11/13/2026
Exhibit Information
EXHIBIT 1
WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;
NOW, THEREFORE, the parties hereto agree as follows:
Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.
Eventide Asset Management, LLC
Date: November 13, 2026
By: /s/ Peter J. Luiso
Name: Peter J. Luiso
Title: General Counsel
Finny Kuruvilla, M.D., Ph. D.
Date: November 13, 2026
By: /s/ Finny Kuruvilla, M.D., Ph. D.
Name: Finny Kuruvilla, M.D., Ph. D.
Robin C. John
Date: November 13, 2026
By: /s/ Robin C. John
Name: Robin C. John
